Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia

• Hauptverfasser: Bain, Earle E (Verfasst von), Shafner, Laura (Verfasst von), Walling, David P (Verfasst von), Othman, Ahmed A (Verfasst von), Chuang-Stein, Christy (Verfasst von), Hinkle, John (Verfasst von), Hanina, Adam (Verfasst von)
• Format: Buch
• Veröffentlicht: JMIR Publications, 2017-02-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

BackgroundAccurately monitoring and collecting drug adherence data can allow for better understanding and interpretation of the outcomes of clinical trials. Most clinical trials use a combination of pill counts and self-reported data to measure drug adherence, despite the drawbacks of relying on the...